Literature DB >> 8549310

Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.

G Molinari1, G C Schito.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8549310     DOI： 10.2165/00003495-199500492-00048

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  8 in total

1.  In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-08       Impact factor: 3.267

2.  In vitro activity of Bay y 3118, a new quinolone.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

3.  Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

4.  Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group.

Authors:  S Gordon; J M Swenson; B C Hill; N E Pigott; R R Facklam; R C Cooksey; C Thornsberry; W R Jarvis; F C Tenover
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

5.  In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinolone.

Authors:  K D Bremm; U Petersen; K G Metzger; R Endermann
Journal:  Chemotherapy       Date:  1992       Impact factor: 2.544

6.  The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.

Authors:  R Wise; J M Andrews; N Brenwald
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

7.  In vitro activity of Bay Y3118 against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

8.  Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.

Authors:  A Bauernfeind
Journal:  J Antimicrob Chemother       Date:  1993-04       Impact factor: 5.790
  8 in total
  1 in total

1.  Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones.

Authors:  Wolfgang Haas; Christine M Sanfilippo; Christine K Hesje; Timothy W Morris
Journal:  Clin Ophthalmol       Date:  2013-05-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.